Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. Topline data were announced yesterday by the University of California, Los Angeles (UCLA) School of Medicine and presented at the 66th Annual Meeting of the American Academy of Neurology by the study’s lead investigator, Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA David Geffen School of Medicine. Synthetic Biologics Inc (NYSEMKT:SYN) shares after opening at $1.90 moved to $2.10 on last trade day and at the end of the day closed at $1.45 . Company price to cash ratio in past twelve months was calculated as 5.79. Synthetic Biologics Inc (NYSEMKT:SYN) showed a negative weekly performance of -50.1%.
Prothena Corporation plc (NASDAQ:PRTA) a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced the appointment of Arthur W. (“Bill”) Homan as Chief Legal Officer. Prothena Corporation PLC (NASDAQ:PRTA) shares fell -15.77% in last trading session and ended the day on $22.00. PRTA return on equity ratio is recorded as -33.10% and its return on assets is -30.90%. Prothena Corporation PLC (NASDAQ:PRTA) yearly performance is 166.34%.
NeoStem, Inc. (NASDAQ:NBS) and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced the execution of a Services Agreement with IRX Therapeutics, Inc. (“IRX”) under which PCT will provide services to support IRX’s development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient’s immune system to broadly restore immunity and overcome cancer-induced immune suppression. NeoStem Inc (NASDAQ:NBS) shares moved down -5.28% in last trading session and was closed at $5.92 while trading in range of $5.57 – $6.25 – NeoStem Inc (NASDAQ:NBS) year to date (YTD) performance is -13.20%.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on January 30, 2014. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) weekly performance is -29.44%. On last trading day company shares ended up $9.66. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) distance from 50-day simple moving average (SMA50) is -24.72%. Analysts mean target price for the company is $31.00.